Investigating a new cancer treatment using AZA-TDC capsules.
Official title: AZA-TDC CAPSULES FOR USE IN CLINICAL TRIAL
Funded at Irisys, INC. · NIH-10710313 · Data updated 2026-11-12
This study is testing a new cancer treatment called AZA-TDC capsules to see how well it works and how safe it is for patients, and it's looking for people to help find out if this new option is better than what’s already available.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Irisys, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | November 19, 2021 |
| Project end | November 18, 2025 |
| Funding year | 2022 |
| Award (this year) | $177,135 |
| NIH project number | 75N98019D00058-0-759102200001-1 |
| Project ID | NIH-10710313 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cancer who are seeking new treatment alternatives.
✕Less likely to help
Patients who are not diagnosed with cancer or those who have already exhausted all treatment options may not benefit from this research.
What this research studies
This research focuses on the development and clinical trial of AZA-TDC capsules, a new medication aimed at treating cancer. The capsules contain a 4 mg strength formulation that is currently not available on the market. Patients participating in this trial will receive the medication to evaluate its effectiveness and safety in combating malignant neoplasms. The study aims to gather data on how well this new treatment works compared to existing therapies.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with cancer.
How similar studies have gone: Other research has shown promise in developing new cancer therapies, but the specific approach of AZA-TDC capsules is novel.
Where this research is happening
-
Irisys, INC.
San Diego, United States Active
Researchers
- Principal investigator: Giannini, Robert — Irisys, INC.
- Study coordinator: Giannini, Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.